Latest Funding Risk News

Plenti Group Limited has reported record quarterly loan originations of $383.3 million, marking a 32% increase year-on-year and driving its loan portfolio to $2.4 billion. Strong credit performance and strategic funding moves underpin its growth momentum.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Centrex Limited has initiated a $10.4 million entitlement offer to fund essential plant upgrades and strengthen working capital, following a strategic logistics debt restructuring. The raise is pivotal for advancing the Ardmore phosphate project and maintaining financial viability.